Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2018
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Specific figures include:
- Shares Offered: 1,666,667 shares of common stock.
- Offering Price: $6.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option for up to 250,000 additional shares, which was exercised on September 14, 2018.
- Expected Net Proceeds: Approximately $10.5 million (after underwriting discounts, commissions, and estimated offering expenses).
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Roth Capital Partners, LLC. This agreement facilitates the sale of new equity to the public, increasing the company's share count and expected cash liquidity upon closing.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use the net proceeds for working capital and general corporate purposes. Specific potential uses include:
- Licensing or acquiring intellectual property or technologies.
- Capital expenditures.
- Funding possible investments in or acquisitions of complementary businesses, partnerships, or minority investments.
- Repaying indebtedness.
Risks and Contingencies: The closing is expected on September 18, 2018, subject to customary closing conditions. The filing includes standard forward-looking statement disclaimers regarding market conditions and the ability to complete the offering.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (expected September 18, 2018).
- Confirm the total number of shares issued after the full exercise of the over-allotment option.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification obligations.
- Monitor subsequent filings for the actual allocation of proceeds (e.g., specific acquisitions or debt repayments).